Marieke I. G. Raaijmakers

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

R. DeSalle, R. Dummer, A. Narechania, 2016, Oncotarget.

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

R. Dummer, Daniel S. Widmer, M. Levesque, 2013, Immunotherapy.

Metastatic melanoma moves on: translational science in the era of personalized medicine

R. Dummer, M. Levesque, A. Saltari, 2017, Cancer and Metastasis Reviews.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

R. Dummer, J. Haanen, P. Kvistborg, 2018, Cancer Immunology Research.

A new live‐cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies

R. Dummer, Daniel S. Widmer, M. Levesque, 2015, Experimental dermatology.

The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype

G. Berx, J. Marine, D. Huylebroeck, 2020, Cancer Research.

The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.

R. Dummer, J. Haanen, P. Kvistborg, 2016 .